GlaxoSmithKline announces that the U.S. Food and Drug Administration (FDA) has approved Arranon (nelarabine) Injection, a chemotherapy agent, for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
According to GlaxoSmithKline, this use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted
